Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5684962 | Translational Research | 2017 | 6 Pages |
Abstract
Cellular therapy with T-regulatory cells (Tregs) is a promising strategy to control immune responses and restore immune tolerance in a variety of immune-mediated diseases, such as transplant rejection and autoimmunity. Multiple clinical trials are currently testing this approach, typically by infusing a single dose of polyclonal Tregs that have been expanded in vitro. However, evidence from animal models of Treg therapy has clearly shown that antigen-specific Tregs are vastly superior to polyclonal cells, meaning that fewer cells are needed for the desired therapeutic effect. Traditional methods to obtain antigen-specific Tregs include antigen-stimulated expansion or T-cell receptor (TCR) overexpression. However, these methods are limited by low cell numbers, complex manufacturing procedures, and knowledge of patient-specific TCRs which recognize disease-relevant MHC-peptide complexes. Recently, several groups have explored the potential to use chimeric antigen receptors (CARs) to generate antigen-specific Tregs. Here, we discuss the progress in this field and highlight the major outstanding questions that remain to be addressed as this approach moves toward clinical applications.
Keywords
TNBSPBMCTCrTNPEAEHSCTLAPTGFTreg2,4,6-trinitrophenol2,4,6-Trinitrobenzene sulfonic acidCeAcarcinoembryonic antigenHuman leukocyte antigenHLAexperimental autoimmune encephalomyelitistransforming growth factorPeripheral blood mononuclear cellT-regulatory cellsCARwild-typelatency-associated peptideHematopoietic stem cell transplantationchimeric antigen receptorT-cell receptor
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Nicholas A.J. Dawson, Megan K. Levings,